LCLuís Fernando Andrade de Carvalho

Luís Fernando Andrade de Carvalho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luís Fernando Andrade de Carvalho has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ten years of experience with pediatric palliative extubation in a Brazilian pediatric hospital: a retrospective analysis

    by Carolina de Araújo Affonseca, Luís Fernando Andrade de Carvalho, Marcelo Militão Abrantes, Lêni Márcia Anchieta

  • Open Access

    Ten years of experience with pediatric palliative extubation in a Brazilian pediatric hospital: a retrospective analysis

    by Carolina de Araújo Affonseca, Luis Fernando de Carvalho, Marcelo Militão Abrantes, Lêni Marcia Anchieta

    Objective To analyze a cohort of pediatric patients who underwent palliative extubation and identify factors associated with a higher probability of in-hospital death. Method: Retrospective cohort study of pediatric patients who underwent palliative extubation between April 2014 and May 2023. Demographic variables were evaluated, including diagnosis, duration of mechanical ventilation, time between decision and extubation, time and place of extubation, medications used, use of catecholamines before extubation, symptoms, treatment instituted, and hospital outcome. A descriptive analysis, a comparative analysis of hospital outcomes, and a Kaplan-Meier survival curve were performed, with comparison using the log-rank test. Results: Forty-one patients with a mean age of 4.5 years; 51.2% male; 90% with neurological impairment secondary to underlying disease. Most patients were extubated in the Intensive Care Unit. 73.2% used endotracheal tubes; 68.3% died in hospital. Median total mechanical ventilation time: 24 days; time between decision and extubation: 1 day; time between palliative extubation and hospital death: 31.2 hours. Symptoms after extubation were less frequent among patients who received opioids and/or benzodiazepines before extubation (p=0.07). Main symptoms: dyspnea and pain, controlled with opioids/benzodiazepines. Dyspnea after extubation correlated with a higher probability of in-hospital death, and the time to death was shorter among those who received catecholamines 72 hours before or who used morphine/benzodiazepines after extubation. Conclusions: this study in a single center reinforces the importance of considering PE as a care strategy for patients with severe, incapacitating, and irreversible diseases, following the wishes and values expressed by the patient and/or their family.

  • Open Access

    Palliative extubation in pediatrics: a scoping review

    by Carolina de Araújo Affonseca, Luís Fernando Andrade de Carvalho, Lêni Márcia Anchieta


  • Open Access

    Fatal viscerotropic and neurotropic disease after yellow fever vaccine: a rare manifestation leading to diagnosis of severe combined immunodeficiency in an infant

    by Lara Jhullian Tolentino Vieira, Gabriela Assunção Goebel, Yuri Barcelos, Luciana Oliveira Cunha, Luisa Teles Melo Santos, Roberta Maia de Castro Romanelli, Fernanda Gontijo Minafra, Andrea Lucchesi de Carvalho, Luiz Fernando Andrade de Carvalho, Lilian Martins Oliveira Diniz

    Yellow fever vaccine (YFV) is a live attenuated vaccine that can cause a mild infection in immunocompetent patients. However, it may not be self-limiting in patients with inborn errors of immunity (IEI) and may be the first and most severe presentation in these patients. A 10-month-old female infant sought emergency care presenting fever for three days and diffuse exanthema. She was a previous healthy child of consanguineous parents. The child had received YFV 28 days before the onset of symptoms. Upon hospital admission, petechial rash on the limbs and hepatosplenomegaly were noted on physical exam. Laboratory tests showed thrombocytopenia, increased serum aminotransferases and elevated gamma-glutamyl transferase (GGT) and alkaline phosphatase levels. During hospitalization she developed hypoactivity, drowsiness, and hypotonia. The possibility of viscerotropic and neurotropic vaccine associated disease was suspected and a possible primary immunodeficiency disease considered. The patient was tested for antibodies against the yellow fever virus (MAC ELISA) on serum and cerebrospinal fluid (CSF) samples, showing positive IgM results. Immunophenotyping showed low levels of lymphocytes and absence of T-cell receptor excision circles (TREC), leading to diagnose of severe combined immunodeficiency disease (SCID). Despite treatment, after 35 days of hospitalization, she evolved to cardiorespiratory arrest and death. Serious adverse events after administration of the YFV are rare and associated with neurological or visceral involvement in most cases. The unfavorable outcome highlights the importance of neonatal screening for SCID and the clinical suspicion of primary immunodeficiencies in infants who have serious adverse events to live virus vaccines.


  • Severe acute respiratory syndrome in children treated at a pediatric referral hospital in Brazil during the COVID-19 pandemic

    by Daniela Caldas Teixeira, Júlia Martins Azevedo Eyer Thomaz, Maria Luiza Custódio Soares, Lara Jhullian Tolentino Vieira, Matheus Matos Mohallem, Ana Luíza Garcia Cunha, Luís Fernando Andrade de Carvalho, Aline Almeida Bentes, Roberta Maia de Castro Romanelli, Lilian Martins Oliveira Diniz

    Background - Although we have accumulated knowledge along with the pandemic, there are still gaps, including the impact of seasonal conditions of SARS-CoV-2 and other respiratory viruses. Methods - A retrospective cohort study that aimed to describe the etiological diagnosis and compare the clinical presentation and outcomes of children with Severe Acute Respiratory Syndrome (SARS). Results – 1,027 children diagnosed with SARS were evaluated. In 926 (90.2%) children who collected RT-PCR Covid, 2.3% had a positive result. A total of 365 (35.4%) of the children underwent collection for Viral Panel exam, with identification of the etiology in 28%. There was a statistically significant difference in the age of patients infected with RSV and other viruses. The length of hospital stay was statistically different (p:0.006) when comparing groups of rhinovirus with COVID or RSV. Conclusion - This study is a pioneer in conducting large-scale testing for respiratory viruses in pediatric patients during the pandemic and contributes to the knowledge about the etiology of SARS in childhood, and this disease's relationship with the seasonality of respiratory viruses.

  • Open Access

    Palliative extubation: five‐year experience in a pediatric hospital

    by Carolina de Araújo Affonseca, Luís Fernando Andrade de Carvalho, Renata de Pinho Barroso Quinet, Maíla Cristina da Cunha Guimarães, Verônica Ferreira Cury, Alexandre Tellechea Rotta

  • Open Access

    Palliative extubation: five-year experience in a pediatric hospital

    by Carolina de Araújo Affonseca, Luís Fernando Andrade de Carvalho, Renata de Pinho Barroso Quinet, Maíla Cristina da Cunha Guimarães, Verônica Ferreira Cury, Alexandre Tellechea Rotta


  • Open Access

    Distúrbio de coagulação em crianças e adolescentes com traumatismo cranioencefálico moderado e grave

    by Carolina A. Affonseca, Luís Fernando A. Carvalho, Sérgio D. Guerra, Alexandre R. Ferreira, Eugênio M. A. Goulart

    OBJETIVOS: Descrever o perfil epidemiológico de crianças e adolescentes com traumatismo cranioencefálico moderado e grave internados em unidade de tratamento intensivo; descrever a freqüência de alterações na coagulação destes pacientes; determinar a relação entre a coagulopatia e a gravidade do trauma; analisar os fatores associados à coagulopatia; e verificar a influência da coagulopatia na mortalidade desses pacientes. MÉTODOS: Estudo transversal com 301 pacientes de até 16 anos internados em terapia intensiva devido a traumatismo cranioencefálico moderado e grave, compreendendo período de 5 anos. O perfil de coagulação foi associado com achados clínicos, epidemiológicos e tomográficos. Análises univariada e multivariada foram empregadas para verificar a associação entre presença de coagulopatia e mortalidade. RESULTADOS: A idade mínima foi de 23 dias, e a máxima, de 16 anos (média de 7,9 anos). Cerca de 77% dos pacientes apresentaram coagulopatia, cuja ocorrência esteve diretamente associada à gravidade do trauma, mas não ao aumento da mortalidade. Os fatores associados com a presença de coagulopatia foram: gravidade do traumatismo cranioencefálico (OR = 2,83; IC95% 1,58-5,07), diagnóstico de edema e ingurgitamento cerebral à tomografia computadorizada de crânio (OR = 2,11; IC95% 1,13-4,07) e ocorrência de trauma torácico e/ou abdominal (OR = 2,07; IC95% 1,11-4,00). Aproximadamente 35% dos pacientes morreram. Em análise multivariada, os fatores que se relacionaram ao aumento do risco de morrer foram: ocorrência de distúrbios de sódio (OR = 5,56; IC95% 2,90-10,65), hipotensão no centro de tratamento intensivo (OR = 12,58; IC95% 4,40-35,00) e síndrome do desconforto respiratório agudo (OR = 13,57; IC95% 1,51-121,66). CONCLUSÃO: O surgimento de coagulopatia é uma complicação freqüente nos pacientes vítimas de traumatismo cranioencefálico moderado e grave. Apesar de, neste estudo, não estar diretamente associada à ocorrência de óbito, pode ser considerada um marcador de gravidade.